NUCLIDIUM and PharmaLogic Form Strategic Partnership for Sustainable Development of Novel Copper-based Theranostics to Diagnose and Treat Solid Tumours
NUCLIDIUM and University Hospital Basel Receive NETRF Investigator Award to Initiate Phase 1 Trial with Novel Copper-based Radiotheranostic Program TraceNET in Neuroendocrine Tumours
Our CEO Leila Jaafar will present the company and our unique copper-based approach at the upcoming conferences. Meet us there!
Nuclidium has won a second Innosuisse Grant of €800.000 to improve treatment of carcinomas via precision imaging of the tumour microenvironment with a novel Copper-61-based PET tracer.
The European Innovation Council (EIC) has awarded Nuclidium with its Accelerator grant of €2,5 million to develop novel, broadly available Copper-based PET tracers for the diagnosis of a broad range of cancer indications.
Innosuisse has awarded Nuclidium with a €1 million grant to further advance its development of a proprietary platform of novel PET tracers based on Copper-61.
